Hyperglycemia and Advanced Glycation End Products Regulate miR-126 Expression in Endothelial Progenitor Cells

J Vasc Res. 2016;53(1-2):94-104. doi: 10.1159/000448713. Epub 2016 Sep 28.

Abstract

Background/aims: Dysfunction of endothelial progenitor cell (EPCs) contributes to diabetic vascular disease. We reported that downregulated miR-126 in diabetic patients causes EPC dysfunction. The study was designed to investigate how high glucose (HG) and advanced glycation end products (AGEs) regulate miR-126 expression and whether miR-126 mediates the effects of HG and AGEs on EPCs.

Methods: We first tested the effects of glucose (5.5-50 mM) and AGEs at 50-200 mg/l on EPC proliferation and selected HG at 50 mM and AGEs at 50 mg/l for further experiments. EPCs were stimulated with HG and AGEs, and miR-126 expression was measured by real-time PCR. Reactive oxygen species (ROS) were measured by immunofluorescence microscopy and flow cytometry. IL-6 and TNF-α levels in EPC supernatants were determined by ELISA. The effects of miR-126 on ROS and inflammatory markers under stimulation of HG and AGEs were also assessed. Finally, the effects of inhibitors of PI3K and Akt on AGE-mediated miR-126 expression were examined.

Results: HG and AGEs increased IL-6, TNF-α and ROS and decreased miR-126 expression in EPCs. miR-126 negatively regulated IL-6, TNF-α and ROS. miR-126 overexpression reduced and miR-126 inhibition further increased the inflammatory markers and ROS induced by HG and AGEs. Inhibitors of PI3K and Akt further decreased miR-126 expression in the presence of AGEs.

Conclusions: In conclusion, hyperglycemia and AGEs decrease miR-126 expression in EPCs. Recovering miR-126 expression may protect EPCs against dysfunction induced by HG and AGEs.

MeSH terms

  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / genetics
  • Diabetes Mellitus, Type 2 / metabolism*
  • Diabetes Mellitus, Type 2 / pathology
  • Dose-Response Relationship, Drug
  • Down-Regulation
  • Endothelial Progenitor Cells / drug effects*
  • Endothelial Progenitor Cells / metabolism
  • Endothelial Progenitor Cells / pathology
  • Feedback, Physiological
  • Glucose / toxicity*
  • Glycation End Products, Advanced / toxicity*
  • Humans
  • Inflammation Mediators / metabolism
  • Interleukin-6 / metabolism
  • MicroRNAs / genetics
  • MicroRNAs / metabolism*
  • Oxidative Stress / drug effects
  • Phosphatidylinositol 3-Kinase / metabolism
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Kinase Inhibitors / pharmacology
  • Proto-Oncogene Proteins c-akt / antagonists & inhibitors
  • Proto-Oncogene Proteins c-akt / metabolism
  • Reactive Oxygen Species / metabolism
  • Signal Transduction / drug effects
  • Time Factors
  • Transfection
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Glycation End Products, Advanced
  • Inflammation Mediators
  • Interleukin-6
  • MIRN126 microRNA, human
  • MicroRNAs
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Kinase Inhibitors
  • Reactive Oxygen Species
  • Tumor Necrosis Factor-alpha
  • interleukin-6, mouse
  • Phosphatidylinositol 3-Kinase
  • Proto-Oncogene Proteins c-akt
  • Glucose